chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Asthma symptoms started 9/17. Coughing and chest tightness. Symptoms progressed 9/18 & 9/19. Skin itching started in the evening on 9/18 with poor sleep and bad dreams. 9/19 skin erupted in viral rash covering most of front torso.
Mother reports swelling, hotness, tenderness starting approximately 3 days after vaccine. Treated her with TYLENOL and BENADRYL cream. Did not visit doctor but called and discussed with her APN.
Flu shot admin 12/7/12 - 8:30 AM, 4 hours later felt itching & developed fine red bumps around eyes and ears. Approximately 2:30 pm subconjunctival hemorrhage (B). Next AM eyes were swollen shut.
Pt described rash, redness and warmth to the area where he was vaccinated on last Fri.  I advised pt to apply cold pack to area and to contact Dr to evaluate.
Blurry vision, extreme joint pain, inability to focus, stiff lymph nodes in neck on same side as injection (left), heart palpitations, heart racing while trying to sleep, reduced cardiovascular output for several months (affected working out). Blurry vision still comes and goes, joint pain is very slowly improving, and cardiovascular output varies (appears to be improving).
Patient experienced dizziness, BP 126/86, HR 69, RR16, 15 mins later BP 131/81, HR73, RR16. Patient stable and released from vaccination site.
Diarrhea; This is a spontaneous report from a contactable consumer (patient). A 28-years-old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 m-RNA VACCINE; formulation: solution for injection, Batch/Lot number: EL3248), dose 1 via an unspecified route of administration, administered in left arm on 01Mar2021 at 12:15 hours as dose 1, single (at the age of 28-years-old) for COVID-19 immunisation. The patient's medical history included anxiety. Concomitant medications included sertraline hydrochloride (ZOLOFT) received within 2 weeks of vaccination. The patient has no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 01Mar2021, the patient experienced diarrhea. The event was reported as non-serious and did not result in death/life threatening/caused/prolonged hospitalization/congenital anomaly/birth defect. The patient received no treatment for the adverse event. The patient confirmed that the date the patient experienced the reported event was on 01Mar2021 and reported the information on 03Mar2021. The clinical outcome for the event was not recovered. No follow-up attempts are needed. No further information is expected.
PATIENT REPORTS REDNESS/SWELLING AT INJECTION SITE. APPROXIMATELY THE SIZE OF QUARTER AS OF 10/19/2015.  PATIENT STATES FEELS WARM TO TOUCH AND FIRM IN RED AREA.   NO HIVES. NO FEVER. NO PUS.
Pain at injection site and down arm; red streaking around arm; temperature up to 101*F (4-8-10)
1st and 2nd doses of vaccine series administered to patient under the age of 16. No known adverse outcomes recorded.
developed a large red spot not at the injection site; This case was reported by a other health professional via sales rep and described the occurrence of localized erythema in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (refer case US2020AMR014835) and NSAIDS (received on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced localized erythema. The patient was treated with ace inhibitor nos (Ace Inhibitor). Rechallenge with Shingrix was positive. On an unknown date, the outcome of the localized erythema was recovered/resolved.   The reporter considered the localized erythema to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The patient experianced large red spot after every shigrix vaccination. The large red spot not at the site of administration but red spot at few inches from site of administration. The patient was fine but think about red spot which are not at site of administration. The reporter consented to follow up.
Hives from Head to Toe (severe)/ 1 massive hive on each, one on each lower glute; Legs swollen because hives got intense; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives from Head to Toe (severe)/ 1 massive hive on each, one on each lower glute) and PERIPHERAL SWELLING (Legs swollen because hives got intense) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032H1A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In December 2021, the patient experienced PERIPHERAL SWELLING (Legs swollen because hives got intense). On 16-Dec-2021, the patient experienced URTICARIA (Hives from Head to Toe (severe)/ 1 massive hive on each, one on each lower glute). The patient was treated with FEXOFENADINE HYDROCHLORIDE (ALLEGRA [FEXOFENADINE HYDROCHLORIDE]) ongoing since an unknown date at a dose of Anti-histamine Allegra OD at daytime; ACRIVASTINE (BENADRYL [ACRIVASTINE]) ongoing since an unknown date at a dose of Benadryl ODl at bedtime and PREDNISONE (oral) ongoing since an unknown date at a dose of Prednisone for Oral steroid. 20mg for each. At the time of the report, URTICARIA (Hives from Head to Toe (severe)/ 1 massive hive on each, one on each lower glute) had not resolved and PERIPHERAL SWELLING (Legs swollen because hives got intense) outcome was unknown.            No concomitant medication was reported. Patient consulted Urgent care on 29 DEC 2021. HCP prescribed Anti-histamine Allegra, Benadryl at bedtime, Prednisone for Oral steroid, 20mg for each.
Pfizer on 3/16 and 4/6. Positive on 8/11 admitted on 8/11-current
Twinrix: 3rd dose earlier than recommended interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 74-year-old male patient who received HAB (Twinrix) for prophylaxis.   Previously administered products included Twinrix (received 1st dose on 18th November 2022). Concomitant products included HEPATITIS A VACCINE + HEPATITIS B VACCINE (TWINRIX).   On 17-MAR-2023, the patient received the 3rd dose of Twinrix. On 17-MAR-2023, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: Twinrix: 3rd dose earlier than recommended interval). The outcome of the drug dose administration interval too short was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 18-MAY-2023 The reporter reported that a patient got the 3rd dose of Twinrix early at month 4 instead of the recommended 6month interval. The reporter consented to follow up. The patient received 3rd dose of Twinrix earlier than the recommended schedule, which led to shortening of vaccination schedule.
About 4:30pm  started getting headache, next day still had headache, chills, tired
she had side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (she had side effects) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (she had side effects). At the time of the report, VACCINATION COMPLICATION (she had side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications was provided by the reporter. No treatment medications was provided by the reporter.  This is a spontaneous case concerning a female patient of unknown age with no relevant medical history, who experienced the unexpected, non serious event of vaccination complication. The event vaccination complication (unspecified) occurrence unknown with respect to the unknown dose number of mRNA-1273 vaccine. The rechallenge was not applicable since the only information disclosed was with this unknown dose number. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 19-Nov-2021: follow-up received contain no significant information; Sender's Comments: This is a spontaneous case concerning a female patient of unknown age with no relevant medical history, who experienced the unexpected, non serious event of vaccination complication. The event vaccination complication (unspecified) occurrence unknown with respect to the unknown dose number of mRNA-1273 vaccine. The rechallenge was not applicable since the only information disclosed was with this unknown dose number. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Exactly ONE WEEK after I had the 2nd dose of Pfizer, both my arms began to tingle and hurt by 2 pm on a Monday.  Within a few hours, this spread to my entire body; every joint and muscle was in severe pain and discomfort.  I went to bed around 5 pm and had the chills, but no fever.  I continued with this pain for Monday night and could barely sleep.  It continued but not as severe on Tuesday and Wednesday.  By Thursday, I forced myself to take a shower.  By Thursday, the pain in the upper body was gone, but I still had severe pain in both lower legs from the knees down.  It was unbearable if I stood for more than 20 seconds, however, if I lifted each leg and then alternated legs, the pain would go away.  This felt like enormous pressure in my legs and at one point, I thought maybe I had blood clots, but my legs were not red or swollen.  The lower leg pressure finally went away on its own by Sunday, April 25th, 2021.  At no point did I have a fever and I could get some relief by taking Ibuprofen, but not a lot of relief.
Facial numbness reported. Started approximately 3 hours post vaccination, improved over 3 days, but then worsened on day 5, and is again improving. The facial numbness was constant on day 5 (3/12/22), and is better today; it is intermittent. Patient feels well otherwise.
Case was hospitalized for Covid 7 months after completing the Covid vaccine series.  In summary, he is an immunocompromise patient on Rituxan, who was recently discharged from the hospital after being admitted for COVID-19 infection, patient was taking dexamethasone and requiring 2 or 3 L of oxygen at home, nonetheless respiratory failure got much worse and despite the fact that he received a couple of vaccines in the previous months he has no antibodies against COVID-19 for which he received monoclonal antibodies on this admission.   He was a started on Remdesivir and dexamethasone but quickly deteriorated for which after discussing pros and cons he received one-time dose of Tocilizumab with excellent response to the treatment. Patient was at some point requiring 40 L of oxygen by high flow nasal cannula in the intensive care unit and now is currently on room air saturating between 89 and 92% feeling comfortable.   He is going to go home with 5 more days of dexamethasone to complete a bit more of 10 days. He has 1 refill at hand and has been instructed to take it back immediately if he feels that the symptoms get much worse after he runs out of the medication.   In addition, respiratory therapist provided him with an oxygen tank in case that he needs it while walking.   He should follow-up with PCP and we will try to see him back telemedicine in the infectious disease clinic over the next week
INSOMNIA; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's concurrent conditions included arrhythmia. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced insomnia. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of insomnia was not reported. This report was non-serious.
no additional adverse event; Patient was administered VARIVAX via intramuscular route, instead of subcutaneous route; This spontaneous report was received from a nurse and refers to a 29 year old male patient. The patient's concurrent conditions, medical history and concomitant medications were not reported.  On 23-JUN-2021, the patient was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) lot # T025942,  expiration date 30-JUL-2022, intramuscularly (instead of subcutaneous route) for prophylaxis (dose and frequency not reported). No additional adverse events were reported.
I contracted COVID-19 on 10/30/22 with symptoms of cough, runny nose, chills, and fever. I was prescribed PAXLOVID on 11/2/22. My symptoms began to resolve after 5 days of illness. I am fully recovered with no lingering symptoms.
Tested COVID positive, symptoms include chills, shortness of breath,  and diarrhea.
Information has been received from a pharmacist concerning a female patient with a history of "aversion" to the needles who was vaccinated with the first dose of GARDASIL "last week". The patient also was vaccinated with PNEUMOVAX 23. Immediately after the vaccination the patient fainted and developed convulsion. The patient also experienced convulsion. The patient was taken to the hospital as a precaution. At the time of report the patient's status was unknown. Upon internal review, convulsion was determined to be an other important medical event. Additional information has been requested.
This non-valid, spontaneous report was received from a registered nurse, referring to an unspecified number of patients of unknown age and gender. No information was provided regarding the patients' medical history, previous drug reactions, allergies, concurrent medical conditions or concomitant medications. On unknown dates, the patients were vaccinated with improperly stored doses of LIQUID PEDVAXHIB lot number N034005 (expiration date 31-JAN-2020) and lot number reported as "N021920" (expiration date 07-FEB-2020) for prophylaxis (doses, routes and anatomical locations of administration were not reported). Additionally, the patients were vaccinated with ROTATEQ by oral route, lot number N005078 (expiration dates 22-NOV-2018 and 04-OCT-2018) for prophylaxis (doses were unknown), GARDASIL 9 lot number N020352 (expiration date 10-APR-2020) for prophylaxis (doses, routes and anatomical locations of administration were not provided) and M-M-R II for prophylaxis (dose numbers, routes and anatomical locations of administration were not provided; lot numbers N010496 [expiration date 31-MAR-2019], N014485 [expiration date 10-MAY-2019], and N023149 [expiration date 24-AUG-2019]). The vaccines were reconstituted with sterile diluent which was reported to be properly stored. The doses of all vaccines were exposed to a temperature excursion below 32 degrees Fahrenheit (F) (also reported as 31F) during a time frame of 15 days, which was detected by the Digital Data Logger. There was no prior temperature excursion and no adverse effects were reported. Follow-up information was received from the nurse on 17-DEC-2018. The reporter provided patients' demographics which made the case valid. This report refers to a 4-year-old patient of unknown gender. On 22-JUN-2018, the patient was vaccinated with an improperly stored dose of VARIVAX lot # N021720, expiration date 10-AUG-2019 (exact dose and route of administration were not reported) for prophylaxis. This is one of multiple reports received from the same reporter. Sender's Comments: US-009507513-1807USA011661.
Focal inflammation and swelling in right index finger beginning ~2 weeks after 2nd dose that continued to worsen and led to arthrotomy surgery on 10/18/2021. Focal inflammation and swelling in left ?index? toe starting ~8/2021 that has required use of meloxicam 15mg daily from 9/2021 to present. Diffuse inflammation in major joints such as hips and shoulders beginning 12/2021 that required steroid and NSAID IM shots 12/23/2021 and course of oral therapy with prednisone taped and continued meloxicam.  Symptoms improving with current treatment as of  today 12/26/21
After the vaccine my arm was sore for about a day or two. A couple weeks later I was told I had bronchitis and developed into walking pneumonia.
Patient recieved smallpox and anthrax vaccinations, had a heart attack that may be related to vaccination. Patient has previous history of heart problems. The hospital discharge summary states CAD.
Patient came in for pneumonia shot and had previously received PREVNAR 13 vaccination greater than 2 years ago. Patient was vaccinated with PNEUMOVAX 23 without any adverse reaction noted. Patient came into pharmacy on 8/7/18 approximately 8 PM reporting that his left arm was itchy, red and warm and had been so for a day or so. RPh on duty told patient to elevate arm, ice it, and take diphenhydramine for the itching at an appropriate allergy dose. RPh on duty instructed patient to call his prescriber to report adverse reaction or go to urgent care/ER if symptoms got worse. RPh on duty notified his physician by telephone of the reaction on 8/8/18.
Patient felt light headed 10 minutes after the vaccine. His blood pressure was elevated 159/93. Pt stated he has been having high blood pressure recently. He felt better after drinking water. the repeat blood pressure after 15 minutes was 145/92.
has healed herself 99% from  GARDASIL; This spontaneous report was received from unspecified reporter and refers to a female of an unknown age..  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection,  (strength, dose description, lot #, expiry date, route of administration, and indication were not provided).  On an unknown date, the patient has healed herself 99% from  GARDASIL. At the time of reporting, the patient was recovering from the event  The causal relationship between has healed herself 99% from  GARDASIL and quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) was unknown.
Patient had been living independently prior to vaccine.  But shortly after her first vaccine, she developed increased difficulty with her memory.  Unable to consistently remember how to manage finances, set up regular medications, use new protocols for safety to avoid contracting COVID.  She needed reminders set up through her home.  She developed a hammer finger prompting more support by her family for activities of daily living, which prompted observation of her memory related struggles. She was also unable to follow the instructions for the new hammer finger suggested by ER and the Physical therapy she received. She needed prompts for activities she had previously taken pride in managing all her life.  She was shortly thereafter referred by her PCP for neurological assessment and in April 2021 was diagnosed with Major Cognitive Disorder Vascular Dementia.  She is now in a Memory Care Facility.  These life changing events seemed to come rather suddenly for someone who had no acute medical event prompting a shift from independence to dependence in a relatively short amount of time.  I am not sure if this is causally related to the vaccine or just correlated in time with when the vaccine was received.
Starting Saturday 10/14/23 patient states her R arm became very sore and continues to be extremely sore today 10/18/23.  There is no visible sign of administration on her arm. She has very hard time lifting her arm up above her head without assistance. She has tried Tylenol & Aleve without any relief.
Information has been received from a physician concerning an 11 year old female patient who on 03-NOV-2010 was vaccinated with the first dose (reported as 0.5 mg) of GARDASIL (lot number not reported) IM. The physician reported that on 03-NOV-2010 the patient experienced general numbness all over the body, after being injected with GARDASIL. Therapy with GARDASIL was discontinued. At the time of the report the patient's outcome was unknown. The patient sought unspecified medical attention. Additional information has been requested.
Symptoms were: general allergic reaction with hives followed by a seizure and spontaneous recovery. Pt relates Seizure was consistent with her normal seizures but slightly worse. She had a seizure 1 week ago and has seizures in clusters, this was consistent with the waning period of the current cluster. Vital signs were (abnormal with tachycardia and hypertension on arrival to the ED). Exam was notable for neck pain. Patient was treated with Benadryl on scene and with Toradol and fluids in the ED and symptoms recovered but multiple shaking episodes characterized by patient as seizure. Patient was observed in the emergency department for an extended period.
Patient has not had an adverse reaction to this vaccination as of time of reporting. The report is for a vaccination error, vaccine booster was given too early--not 6 months after completion of initial 2 dose series of mRNA. Moderna #1 given 4/20/2021 lot 031A21A, Moderna #2 given 6/2/2021 lot 020B21A, Pfizer booster given today, 11/15/2021 lot FF2589.
w/in 2-3 hrs following vax pt exp t101.2 ax, high pitched crying/screaming, blue discoloration of feet & legs, local react @ inject site; APAP given, fussy, some appetite loss;
THE INTERN PHARMACIST PROVIDED THE VACCINE IN DESIGNATED VACCINE ROOM. VACCINE  WAS ADMINISTERED AT 12:20 PM. AS INTERN WAS CLEANING ROOM, KNOCKING WAS HEARD AT VACCINE ROOM DOOR AND PATIENT'S FRIEND/SIGNIFICANT OTHER STATED THAT PATIENT HAD FAINTED IN A CHAIR AROUND 12:22 PM. WHILE 911 WAS BEING CALLED AT 12:24 PM PATIENT WAS ALREADY CONSCIOUS. ACCORDING TO PATIENT'S FRIEND/SIGNIFICANT OTHER, PATIENT SAT DOWN IN CHAIR AND THEN PASSED OUT FOR APPROXIMATELY 20-30 SECONDS BEFORE BECOMING CONSCIOUS AND WAS CONSCIOUS WHEN PARAMEDICS ARRIVED. PATIENT LOOKED PALE AND STATED TO FEEL WEAK. PATIENT WAS PROVIDED WATER WHILE WAITING FOR PARAMEDICS TO ARRIVE AND STATED TO FEEL BETTER. WHEN PARAMEDICS ARRIVED, VITALS WERE CHECKED AND BP WAS LOW. PATIENT WAS THEN TAKEN TO HOSPITAL DUE TO PROGRESSIVELY FEELING WORSE (WEAK).